COMMUNIQUÉS West-GlobeNewswire

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
02/06/2025
Media Release COPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), [...]
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
02/06/2025
Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP [...]
Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference
02/06/2025
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President [...]
LifeLabs partners with POGO to support their ongoing mission of helping Ontario children with cancer
02/06/2025
Toronto, Ontario, June 02, 2025 (GLOBE NEWSWIRE) -- LifeLabs, Canada’s leading medical laboratory, is proud to announce its continued partnership with the Pediatric Oncology Group of Ontario (POGO) to support Canadian [...]
Abivax Presents First Quarter 2025 Financial Results
02/06/2025
Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage [...]
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2025
ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted 10 newly-hired [...]
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
02/06/2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the [...]
The Ensign Group Acquires Two Skilled Nursing Facilities in Idaho
02/06/2025
SAN JUAN CAPISTRANO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Adds Skilled Nursing Facility in California
02/06/2025
SAN JUAN CAPISTRANO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2025
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 30, 2025, the [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2025
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly [...]
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
02/06/2025
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in [...]
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
02/06/2025
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Sernova Appoints Jonathan Rigby as Interim Chair
02/06/2025
LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid [...]
Vaxart Announces Adjournment of Annual Meeting of Stockholders
02/06/2025
Meeting adjourned to June 13, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025 Leading Independent [...]
Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes
02/06/2025
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of [...]
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2025
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units (“RSUs”) to six newly-hired non-executive [...]
First Insight Unveils New MaximEyes Brand Website to Reflect Innovation in Eye Care Technology
02/06/2025
PORTLAND, Ore., June 02, 2025 (GLOBE NEWSWIRE) -- First Insight Corporation, a leader in eye care software solutions, today announced the official launch of a refreshed visual identity and redesigned website for its [...]
Harvard Bioscience Appoints John Duke to Board of Directors
02/06/2025
HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will [...]

Pages